Kiora Pharmaceuticals Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
/ 
Frequently asked questions
To buy Kiora Pharmaceuticals Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Kiora Pharmaceuticals Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Kiora Pharmaceuticals Inc. is KPRX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Kiora Pharmaceuticals Inc. has its primary listing on NASDAQ (Small cap). You can trade Kiora Pharmaceuticals Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Kiora Pharmaceuticals Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Kiora Pharmaceuticals Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Kiora Pharmaceuticals Inc..